Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

76.35USD
26 Apr 2017
Change (% chg)

$0.11 (+0.14%)
Prev Close
$76.24
Open
$75.63
Day's High
$76.65
Day's Low
$75.62
Volume
478,451
Avg. Vol
605,063
52-wk High
$83.58
52-wk Low
$66.93

Select another date:

Tue, Apr 25 2017

Novartis to speed up bid for MS drug approval, changes target

ZURICH Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease.

Novartis to speed up bid for MS drug approval, changes target

ZURICH Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease.

Novartis to speed up bid for MS drug approval, changes target

ZURICH, April 25 Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease.

Novartis sets sights on return to growth in 2018

ZURICH Novartis reported better-than-expected first-quarter profits on Tuesday with Chief Executive Joe Jimenez saying he remained confident the Swiss drugmaker would return to growth in 2018 as spending to promote new drugs pays off.

UPDATE 3-Novartis sets sights on return to growth in 2018

* Advances MS drug BAF312 filing date to 2018 from 2019 (Adds $200 mln hit from drug trial failure, closing share price)

BRIEF-Novartis's Sandoz head says sees generics price pressure in China

* CFO Harry Kirsch says sales of the Swiss drugmaker's newly approved breast cancer drug Kisqali to be modest in the first half of 2017 before accelerating in the final six months

BRIEF-Novartis CEO says takeover prices have risen, focusing on early-stage targets

* CEO Joe Jimenez says thinks with Cosentyx "we can hold our own" against lilly drug taltz

Novartis Q1 profit slips as spending on Alcon, Entresto continue

ZURICH, April 25 Novartis's first-quarter core net income fell 4 percent, it said on Tuesday, as the Swiss drugmaker's spending to kick start sales at its eyecare unit Alcon and for its heart failure drug Entresto weighed again on earnings.

BRIEF-Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine

* Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine

J&J, Novartis and Takeda in talks for Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout, two people with knowledge of the matter said on Monday.

Select another date:

More From Around the Web